Full-Time

Senior Manager

Posted on 9/11/2026

Deadline 9/18/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

Compensation Overview

$134.7k - $176.8k/yr

Mississauga, ON, Canada

Hybrid

Three days in the office per week are generally expected.

Bachelor's, Master's, MBA

Category
Sales & Account Management (1)
Required Skills
LLM
Sales
Regression
SQL
CRM
Electronic Health Records (EHR)
Tableau
Data Analysis

Get referred to Alexion

See people who can refer or advise you

Requirements
  • A bachelor’s degree in a relevant field.
  • At least 4 years of experience in advanced analytics, business insights, reporting, sales operations, or related commercial functions, ideally within the pharmaceutical or biotechnology industry.
  • Deep knowledge of data manipulation, harmonization, and integration for analytics purposes.
  • Experience in user-centric dashboard design and development.
  • Experience building mockups, markups, and proofs of concept.
  • Ability to translate business needs into technical requirements and drive outcomes across cross-functional teams.
  • Ability to identify data quality concerns, drive resolution, and improve the reliability of analytical outputs.
  • Experience communicating and presenting across multiple organizational levels, including senior stakeholders.
  • Experience gathering requirements and managing stakeholders across functions.
  • Demonstrated ability to lead complex projects independently and manage ambiguity effectively.
  • Ability to generate insights from complex and disparate data sources and translate findings into actionable business recommendations.
  • Broad experience with US markets, project management, and written and verbal communication.
  • Experience with external data such as claims data, electronic medical records, and third-party data.
  • Experience with customer relationship management, alignment, and analytical applications.
  • Demonstrated capability to apply data literacy, prompt engineering, and systems thinking to advance sales operations and strategic insights using artificial intelligence.
  • Experience designing artificial-intelligence-enabled solutions and defining business requirements for how artificial intelligence should analyze and interpret field-relevant data.
  • Ability to travel less than 10%.
  • Fluency in English, both written and oral.
  • Ability to work in an office environment, use a computer, communicate by phone, video, and electronic messaging, solve problems, analyze information, collaborate with others, and maintain availability during standard business hours.
Responsibilities
  • Serve as a strategic partner to executive sales directors, regional sales directors, business unit leaders, and senior commercial stakeholders.
  • Lead complex analyses and recurring workstreams supporting field sales strategy, execution, and performance management for the aligned business unit.
  • Partner with field sales and commercial stakeholders to identify business needs, assess performance trends, and develop recommendations to strengthen execution.
  • Evaluate sales force execution and business performance drivers and translate findings into next-best-action recommendations.
  • Support the associate director and commercial leadership in converting strategic priorities into measurable operational plans and insight deliverables.
  • Own and lead high-priority analyses of sales, activity, competitive market, and performance data to identify trends, opportunities, and risks.
  • Translate complex and ambiguous business questions into structured analytical approaches, insight narratives, and decision-ready recommendations.
  • Lead development of business reviews, dashboards, reports, and analytics tools supporting field leaders, business unit partners, and commercial stakeholders.
  • Define business requirements for customer relationship management, dashboard, and reporting enhancements and partner with technical teams to drive delivery.
  • Lead the design of artificial-intelligence-enabled use cases that improve insight generation, streamline manual processes, and strengthen field execution.
  • Lead cross-functional execution for assigned initiatives across commercial operations, data, reporting, customer relationship management, master data management, and partner teams.
  • Ensure analytics and operational solutions align with stakeholder requirements and are delivered with high quality.
  • Implement standards and ways of working that improve consistency, role clarity, and compliant go-to-market execution.
  • Provide operational and analytical partnership for field-based stakeholders and help ensure insights are translated into action.
  • Lead multiple complex workstreams simultaneously by setting expectations, managing dependencies, communicating with stakeholders, and maintaining project priorities.
  • Build integration with commercial operations partners and engage appropriate stakeholders at key stages of work.
  • Provide guidance and informal coaching to less experienced team members in support of high-quality deliverables.
  • Ensure analyses, recommendations, and operational processes are conducted compliantly and in line with company values and standards.
  • Use project management tools and structured ways of working to prioritize, track, and resource assigned initiatives.
Desired Qualifications
  • An MBA or advanced degree in a quantitative, business, or analytical discipline.
  • Prior experience in rare disease.
  • Experience in advanced analytics in healthcare, research or consulting, or pharmaceutical or biotechnology organizations.
  • Expertise in analytical tools such as SQL, Qlik, and Tableau.
  • Experience with master data management.
  • Statistical, regression, and other analytical skills.
  • Sales experience.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old